---
title: "Krystal Biotech files patent response citing single-patient KB801 corneal closure"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293389611.md"
description: "Krystal Biotech filed a USPTO response for its KB801 gene therapy patent, disclosing complete closure of a persistent corneal epithelial defect in one patient from a discontinued study. The company stated the study was halted to advance KB801 into pivotal trials, with no safety concerns observed. This single-patient data was shared via the patent record for public access, though the company cautioned it is not top-line trial results."
datetime: "2026-07-21T21:33:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293389611.md)
  - [en](https://longbridge.com/en/news/293389611.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293389611.md)
generator: "portal-rs"
---

# Krystal Biotech files patent response citing single-patient KB801 corneal closure

**Krystal Biotech disclosed a single-patient corneal epithelial defect closure in a patent office response for KB801.**

**Key Highlights:**

-   Filed a USPTO response for a published patent application covering KB801, its gene therapy for neurotrophic keratitis.
-   Response included data showing complete closure of a persistent corneal epithelial defect in one patient from a discontinued study.
-   Study was discontinued to advance KB801 into a pivotal trial; no safety concerns or serious adverse events were observed in the study.
-   Company had not previously disclosed the single-patient observation and shared it to ensure public access via the patent record.
-   Company cautions the observation is from one patient, not top-line trial results, and will report pivotal trial results in the ordinary course.

Original SEC Filing: Krystal Biotech, Inc. \[ KRYS \] - 8-K - Jul. 21, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)

## Related News & Research

- [BLX: Record trade growth and Q4 retail rebound drive solid results despite margin pressure](https://longbridge.com/en/news/297117217.md)
- [IMB: Revenue up 16% year-over-year, with acquisitions and cash flow driving future growth](https://longbridge.com/en/news/297110349.md)
- [EH: Revenues soared 203.5% QoQ, but regulatory caution in China clouds near-term outlook](https://longbridge.com/en/news/296894241.md)
- [QBIM: Q2 2026 saw 75% revenue growth, higher margins, and strategic product and financing advances](https://longbridge.com/en/news/297274910.md)
- [BD EVP, Chief Revenue Officer Michael Feld sells 165 shares for $31,100.85](https://longbridge.com/en/news/297229414.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**